Skip to content

Precigen PGEN Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Gilead Sciences logo
Gilead SciencesGILD
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$1.91B+213%
Enterprise value$2B+234%
P/S72×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's deferred tax assets and other non-current assets?
Precigen (PGEN) reported deferred tax assets and other non-current assets of $782K in Q1 2026.
How has Precigen's deferred tax assets and other non-current assets changed year-over-year?
Precigen's deferred tax assets and other non-current assets increased by 83.1% year-over-year, from $427K to $782K.
What is the long-term trend for Precigen's deferred tax assets and other non-current assets?
Over 5 years (2020 to 2025), Precigen's deferred tax assets and other non-current assets has grown at a -10.7% compound annual growth rate (CAGR), from $1.6M to $908K.